On December 17, 2020 CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, reported it will host a conference call and live webcast on December 18th, 2020 at 8:30am ET to discuss its Investigational New Drug (IND) approval for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM), and planned Phase 2 Berubicin clinical trial (Press release, CNS Pharmaceuticals, DEC 17, 2020, View Source [SID1234573006]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the webcast are below:
Date:
December 18th, 2020
Time:
8:30 AM ET
Link:
The dial-in numbers for the conference call are (800) 226-2188 for domestic callers and (602) 563-8462 for international callers. The conference ID is 6455799.
A replay of the call will be available following its completion through December 25th, 2020. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID: 6455799.